Taken together, metformin reduces the motility of vascular smooth muscle cells through the activation of the AMPK–Pdlim5 pathway, which contributes to the protective effects of metformin against diabetes-accelerated atherosclerosis and is beneficial for the therapy of metabolic syndrome. This evidence concerns the gene PRKAA1 and atherosclerosis.